LUPRON DEPOT® (leuprolide acetate for depot suspension) 7.5 mg for 1-month, 22.5 mg for 3-month, 30 mg for 4-month, and 45 mg for 6-month administration are indicated for the palliative treatment of advanced prostatic cancer.
References: 1. LUPRON DEPOT® [package insert]. North Chicago, IL: AbbVie Inc. 2. Spitz A,Young JM, Larsen L, et al. Efficacy and safety of leuprolide acetate 6-month depot for suppression of testosterone in patients with prostate cancer. Prostate Cancer Prostatic Dis. 2012;15(1):93-99. 3. Sharifi R, Dean Knoll L, Smith J, Kramolowsky E. Leuprolide acetate (30-mg depot every four months) in the treatment of advanced prostate cancer. Urology. 1998;51(2):271-276. 4. Data on file ABVRRTI63963. AbbVie Inc. 5. Sharifi R, Bruskewitz RC, Gittleman MC, Graham SD Jr, Hudson PB, Stein B. Leuprolide acetate 22.5 mg 12-week depot formulation in the treatment of patients with advanced prostate cancer. Clin Ther. 1996;18(4):647-657. 6. Data on file ABBRRTI63945. AbbVie Inc. 7. Sharifi R, Soloway M. Clinical study of leuprolide depot formulation in the treatment of advanced prostate cancer. The Leuprolide Study Group. J Urol. 1990;143(1):68-71. 8. Data on file ABBRRTI63942. AbbVie Inc .9. U.S. Food and Drug Administration. Orange Book detail search. Available at: http://www.accessdata.fda.gov/scripts/cder/ob/search_product.cfm. Accessed March 16, 2018. 10. Data on file. AbbVie Inc. LuproLink clinic count. August 31, 2015. 11. Data on file. AbbVie Inc. LuproLink clinic count. April 21, 2015.